KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

IBUGESIC SUSPENSION

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

 

GENERIC NAME:

IBUPROFEN

 

MANUFACTURER:

DAR AL-DAWA DEVP. & INV.CO.

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

B; D , 3rd trimester

 

INDICATIONS:

Arthritis, osteoarthritis

Arthritis, rheumatoid

Dysmenorrhea

Fever

Pain, mild to moderate

 

SIDE EFFECTS:

thrombocytopenia

tinnitus

toxic epidermal necrolysis

urticaria

visual impairment

wheezing

abdominal pain

agranulocytosis

anemia

anorexia

aplastic anemia

aseptic meningitis

azotemia

bleeding

bronchospasm

bullous rash

confusion

constipation

diarrhea

dizziness

drowsiness

dyspepsia

dysphagia

dyspnea

edema

elevated hepatic enzymes

erythema multiforme

esophageal stricture

esophageal ulceration

esophagitis

flatulence

gastritis

GI bleeding

GI perforation

headache

heart failure

hematuria

hemolytic anemia

hepatitis

hyperkalemia

hypertension

hyperuricemia

interstitial nephritis

jaundice

maculopapular rash

nausea/vomiting

nephrotic syndrome

neutropenia

odynophagia

pancreatitis

pancytopenia

peptic ulcer

peripheral edema

photophobia

platelet dysfunction

proteinuria

pruritus

pseudotumor cerebri

pyrosis (heartburn)

rash (unspecified)

renal failure (unspecified)

renal papillary necrosis

Stevens-Johnson syndrome

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

acute bronchospasm

alcoholism

anemia

anticoagulant therapy

asthma

bone marrow suppression

breast-feeding

chemotherapy

coagulopathy

corticosteroid therapy

dental disease

dental work

diabetes mellitus

edema

elderly

GI bleeding

GI disease

heart failure

hematological disease

hemophilia

hepatic disease

hypertension

immunosuppression

intramuscular injections

jaundice

labor

nasal polyps

neutropenia

peptic ulcer disease

pregnancy

renal disease

renal failure

renal impairment

rheumatoid arthritis

surgery

systemic lupus erythematosus (SLE)

thrombocytopenia

tobacco smoking

ulcerative colitis

urticaria

 

ADULT DOSE:

Antirheumatic (nonsteroidal anti-inflammatory) -Oral, 1200 to 3200 mg a day in three or four divided doses. After a satisfactory response has been obtained, dosage should be reduced to the lowest maintenance dose that provides continuing control of symptoms. Note: Higher doses generally are required in rheumatoid arthritis than in osteoarthritis. Analgesic (mild to moderate pain) Antipyretic or Antidysmenorrheal-Oral, 200 to 400 mg every four to six hours as needed.

 

MAXIMUM ADULT DOSE:

Antirheumatic (nonsteroidal anti-inflammatory) -Up to 3600 mg per day. The maximum dosage should be used only if the clinical benefit is increased sufficiently to offset the higher risk of adverse effects. Analgesic Antipyretic; or Antidysmenorrheal-For patient self-medication (over-the-counter use): Not to exceed 1200 mg per day.

 

PEDIATRIC DOSE:

Antirheumatic (nonsteroidal anti-inflammatory) -Infants up to 6 months of age: Safety and efficacy have not been established. Children 6 months to 12 years of age: Oral, initially 30 to 40 mg per kg of body weight a day in three or four divided doses, although 20 mg per kg of body weight per day may be sufficient for patients with mild disease. After a satisfactory response has been achieved, dosage should be reduced to the lowest dose needed to control disease activity. Antipyretic-Infants up to 6 months of age: Safety and efficacy have not been established. Children 6 months to 12 years of age: Oral, 5 mg per kg of body weight for fevers less than 39.17 C (102.5 F) and 10 mg per kg of body weight for higher fevers. Dosage may be repeated, if necessary, at intervals of 4 to 6 hours or more. 

 

MAXIMUM PEDIATRIC DOSE:

Antirheumatic-Oral, 50 mg per kg of body weight per day. Antipyretic-Oral, 40 mg per kg of body weight per day.

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT